Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Raptor, TorreyPines combine in reverse merger

Executive Summary

In a stock-for-stock reverse merger, the CNS-focused TorreyPines Therapeutics will combine with Raptor Pharmaceuticals (targeted drug delivery using human engineered proteins). TPT is issuing Raptor shareholders its common stock so that Raptor will hold about 95% of the merged entity and hopefully grab TPT's NASDAQ listing. (TorreyPines plans a reverse stock split to ensure it complies with NASDAQ listing rules.) The new company will operate under the Raptor name at its Novato, CA headquarters, with Raptor's CEO staying on as head of the combined business.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies